Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03797248
Other study ID # 201801559A3
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date November 12, 2018
Est. completion date October 24, 2020

Study information

Verified date September 2019
Source Chang Gung Memorial Hospital
Contact Ming-Yen Tsai, PhD
Phone +886975056534
Email missuriae@yahoo.com.tw
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This 2-year trial is intended to be used to study breast cancer patients through forward-looking generation design through collaboration between Chinese and Western medical teams. The whole study consists of 2 stages, stage I comprises a cross-sectional study-baseline and stage II is a cohort for outcome evaluation and follow-up study across a 3-year period. To provide an empirical basis for combined TCM treatment in the Breast Cancer Research Team and to publish that as a reference for future TCM and Western medicine in integrative cancer treatment.


Description:

Breast cancer is a major health issue for women worldwide and has increased exponentially in the last decades. Improved earlier detection combined with adjuvant systemic therapy is responsible for much of the reduction in cause-specific mortality from breast cancer. Chemotherapy after surgery can decrease the risk of recurrence and is often used as routine treatment in clinic. Because of the fact that a considerable number of patients seek for traditional Chinese medicine (TCM) during adjuvant chemotherapy, it is thus need to evaluate the correlation between TCM treatment and prognosis. The investigators design a single center, prospective cohort study began in November 2018 in Kaohsiung, Taiwan. A sample of 104 participants diagnosed with early breast cancer was recruited from Breast Cancer Research Team and are followed up every 3 to 6 months till October 2023. Detailed information of participants includes general information, history of cancer, quality of life, side effects of chemotherapy and safety of treatment, body constitution of TCM and meridian energy analysis is taken face-to-face at baseline.


Recruitment information / eligibility

Status Recruiting
Enrollment 310
Est. completion date October 24, 2020
Est. primary completion date October 24, 2020
Accepts healthy volunteers No
Gender Female
Age group 20 Years and older
Eligibility Inclusion Criteria:

- Aged > 20 years old female patients;

- Patients with histologically proven stage 1-3 breast cancer after surgery;

- The duration from the end of radical surgery to the beginning of the trail is less than 1 month;

- ECOG score is 0-2 points;

- Agreed to participate in this study and signed informed consent.

Exclusion Criteria:

- Combined with inadequate heart, liver, kidney and hematopoietic function and other serious diseases;

- Pregnant and lactating women;

- Patients with a history of mental illness;

- Patients with distant metastasis and/or expected lifetime less than 3 months;

- Patients undergoing other medicinal herbs outside our hospital.

Study Design


Related Conditions & MeSH terms


Intervention

Combination Product:
Chinese herbal medicine
All Chinese herbal products prescribed from TCM physicians in our hospital during patients receiving adjuvant chemotherapy

Locations

Country Name City State
Taiwan Kaohsiung Chang Gung Memorial Hospital Kaohsiung

Sponsors (1)

Lead Sponsor Collaborator
Chang Gung Memorial Hospital

Country where clinical trial is conducted

Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Primary disease-free survival 3-year disease-free survival 3 years
Secondary QOLs measurement-1 Functional Assessment of Cancer Therapy - Breast Cancer(FACT-B) 6 months
Secondary QOLs measurement-2 Eastern Cooperative Oncology Group (ECOG) 6 months
Secondary TCM pattern Body Constitution Questionnaire (BCQ) 6 months
Secondary meridian energy Meridian Energy Analysis Device (MEAD) 6 months
Secondary Side effects of adjuvant chemotherapy Common Terminology Criteria for Adverse Events (CTCAE) 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT05528263 - Preventing Chemotherapy-Induced Peripheral Neuropathy With Acupuncture (PACT Trial) N/A
Completed NCT00165243 - Tangential Radiation Therapy Without Axillary Dissection in Breast Cancer Phase 2
Recruiting NCT05559164 - Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted Phase 2
Completed NCT03948568 - Evaluating Optimal Timing of Endocrine Therapy and Radiation Therapy in Early-stage Breast Cancer (REaCT-RETT) Phase 4
Recruiting NCT04553770 - Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer Phase 2
Recruiting NCT06001762 - TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer Phase 2
Active, not recruiting NCT03664687 - Comparing a Single-Dose vs. Twice Yearly Zoledronate in Patients With Early Stage Breast Cancer (REaCT-ZOL) Phase 4
Recruiting NCT04603209 - Registry for Intra-Operative Radiotherapy During Breast Conserving Surgery in Patients With Early Stage Breast Cancer
Completed NCT00233077 - Patient Centered Randomized Controlled Trial N/A
Recruiting NCT02958033 - Shandong Cancer Hospital Affiliated to Shandong University Phase 3
Recruiting NCT03788083 - Intratumoral TriMix Injections in Early Breast Cancer Patients Phase 1
Recruiting NCT05582499 - Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy Phase 1/Phase 2
Recruiting NCT05871437 - Huaier Granule on Reducing the Level of Tumor Markers in Patients With Early-stage Breast Cancer Phase 4
Recruiting NCT04003558 - Deep Learning Algorithms for Prediction of Lymph Node Metastasis and Prognosis in Breast Cancer MRI Radiomics (RBC-01)
Terminated NCT03894007 - Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer Phase 2
Recruiting NCT02982148 - Methylene Blue Intradermal Injection for Sentinel Lymph Node Biopsy for Breast Cancer Patients Phase 4
Active, not recruiting NCT03553797 - Accelerated Whole Breast Irradiation Hypofractionation Plus Boost VS Standard Whole Breast Irradiation Plus Boost Phase 3
Recruiting NCT06215469 - Portable Scalp Cooling System (PSCS) to Prevent Hair Loss for Breast Cancer Patients (Cooler Heads) N/A
Enrolling by invitation NCT06409221 - VISION: Triple Negative Breast Cancer Sample and Clinical Data Acquisition Study
Not yet recruiting NCT05280288 - Effect of the App Bone@BC Version 4.0 Under the Follow-up for Patients With Early Breast Cancer N/A